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Abstract
Lysophosphatidic acid (LPA) and lysophosphatidylcholine (LPC) activity
has been found to be dysregulated in cancer cells and therefore is a crucial
target for research. Only a few LPA receptors have been identified to date,
namely LPA 1, LPA 2, LPA 3, LPA 4 and peroxisome proliferator-activated
receptors (PPAR). In order to identify receptors, we are designing and
synthesizing bifunctional LPA and LPC activity probes to characterize their
protein targets using activity based protein profiling (ABPP) among other
proteomic technologies. By synthesizing bifunctional signaling probes that can
mimic the naturally occurring LPA and LPC molecules and selectively capture
receptors by virtue of their binding properties, we can identify and study the
different proteins that are aberrantly expressed in various pathophysiological
states such as cancer.

iii

Table of Contents
CHAPTER I Introduction ……………………………………………………………1
Background & Significance of Lipid Signaling and LPA Activity………………..2
Biosynthesis of LPA………………………………………………………………….4
LPA Receptors……………………………………………………………………….6
GPCRs and G-Protein Signaling…………………………………………………..8
Activity-Based Protein Profiling (ABPP)………………………………………….10
CHAPTER II Research Design……………………………………………………..16
Experimental Procedure…………………………………………………………...29
References …...……………………………………………………………………....39
Appendix
NMR Spectra………………………………………………………………………….42

Vita……..........……………………………………………………………56

iv

List of Figures
Figure 1. LPA metabolic pathways. ............................................................. ………3
Figure 2. Major LPA signaling pathways involving G-coupled receptors…..….9
Figure 3. Schematic representation of ABPP using probes bearing photoaffinity
tags……………………………………………………………………………………13
Figure 4. Examples of photo-reactive groups…………………………………....14
Figure 5. Target LPA and LPC activity probes……………………………...…...16
Figure 6. Synthesis of the head group…………………………………………....21
Figure 7. Synthesis of the lipid tail………………………………………………...22
Figure 8. Modular synthesis of the alkyne acid………………………………….23
Figure 9. Synthetic strategy for introducing the bifunctional tag………………24
Figure 10. Alternative methods attempted for direct coupling of lipid tails...…25
Figure 11. Attempt to Couple bifunctional tags directly onto diol 4……… …..26
Figure 12. Modular synthetic strategy of the LPA probe…………………….…27
Figure 13. Modular synthetic strategy of the LPC probe…………………….…28

v

List of Abbreviations

ABPP
ATX
cAMP
DCC
DDQ
EDCI
EDG
EGF
FP
GPCR
GDP
GTP
ICAT
IP3
LC-MS
LPA
LPC
LPP
MAPK
Mud-PIT
PAL
PC
PE
PI3K
PIP2
PLA1
PLC
PLD
PPAR
sPLA2
TOP

Activity-Based Protein Profiling
Autotaxin
Cyclic Adenosine Monophosphate
N,N-dicyclohexylcarbodiimide
2,3-dichloro-5,6-dicyanobenzoquinone
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
Endothelial Gene Differentiation
Epidermal Growth Factor
Fluorophosphonate
G protein-coupled receptors
Guanosine Diphosphate
Guanosine Triphosphate
Isotope Coded Affinity Tags
Inositol-(1,4,5)-trisphosphate
Liquid Chromatography Mass Spectrometry
Lysophosphatidic Acid
Lysophosphatidylcholine
Lipid Phosphate Phosphohydrolases
Mitogen-Activated Protein Kinase
Multidimensional Protein Identification Technology
Photo affinity labeling
Phosphatidylcholine
Phosphatidylethanolamine
Phosphatidylinositol-3-kinase
Phosphatidylinositol-(4,5)-bisphosphate
Phospholipase A1
Phospholipase C
Phospholipase D
Peroxisome Proliferator-Activated Receptor
Secretory Phospholipase A2
Tandem Orthogonal Proteolysis

vi

CHAPTER I
INTRODUCTION
Lipids are naturally occurring molecules that play important biological
functions. They are integral structural components of cell membranes and are
important signaling molecules. Eukaryotic cells are composed of a 2-molecule
thick lipid bilayer, which primarily consists of phospholipids containing a
hydrophilic head group and two hydrophobic tails each. 1 The polar head groups
are directed towards the inside (cytoplasm) and to the outside (extracellular
matrix). For a long time, lipids were thought to have minimal biological roles that
were limited to composition of cell membranes and as intermediates in lipid
biosynthesis2. However, later studies revealed how lipids play key roles in cell
signaling that governs specific cellular responses.3 The most abundant
glycerophospholipids

in

cells,

phosphatidylcholine

(PC)

and

phosphatidylethanolamine (PE), had been regarded as passive structural
components of cell membranes for a long period of time. 4 However, studies by
Hokin and Hokin in 1950 described how phosphatidylinositol turnover is induced
by acetylcholine.2 This, alongside with studies by Takai and Kishimoto, which
revealed that their enzymatic activity as cyclic nucleotide-independent kinase is
activated by the active phospholipids in membranes, implies that membranebound lipids play a crucial role in the transmembrane control of important
biological processes and organelle biogenesis, thus underlying their active rather
than passive role in biochemistry of eukaryotic cells.2-3 Studies have shown that
lipid signaling is a vital component of cell signaling and often involves the binding
1

of lipids to protein targets, such as receptors, kinases or phosphatases, which in
turn mediates the effects of these intermediate lipids in important biological
pathways.
Background and Significance of Lipid Signaling and LPA activity
Monoacyl-sn-glycero-3-phosphate, commonly known as lysophosphatidic
acid (LPA, figure 1) has aroused substantial research interest in the recent past,
as its growth-factor-like activity has been found to be upregulated in cancer cells.
The causal role of LPA in cancer is substantiated by studies showing that
metastasis is characterized by increased activity of the enzyme autotaxin, which
produces LPA. Today LPA is known to contribute towards several physiological
and pathophysiological processes in vivo. The discovery of the mitogenic nature
of LPA and its signaling via specific G-protein coupled receptors (GPCRs) in the
1990s stimulated its emergence as a crucial target for research. 5 LPA is today
not only known to be active in several and diverse G-protein-mediated signaling
pathways6, but also activates Ras and Rho/Rac family GTPases to control cell
multiplication, migration and morphogenesis, respectively, and therefore also
plays a role in wound healing and atherosclerosis among other processes. LPA
has been found to be produced in diverse cell types including Schwann cells,
leukocytes, T-lymphoma cells, skin, myofibroblasts, cortical cells, neuronal and
non-neuronal cells.7 In addition, LPA levels are increased in a number of
pathophysiological states including immunodeficiency diseases, ovarian and
other cancer cells and atherosclerosis. This implicates LPA as an important
mediator in the onset of cancer.8
2

Figure 1. LPA metabolic pathways

Therefore, LPA synthesis, signaling, receptors, bioactivity and degradation are
crucial targets for research and therapy of cancer and other diseases.
Lysophosphocholine (LPC, figure 1), is a critical glycerophospholipid
because it acts as a substrate for the enzyme autotaxin (ATX), which performs
phosphate hydrolysis to produce lysophosphatidic acid (LPA). Consequently, it is
an important therapeutic target in medicinal chemistry. However, few inhibitors of
autotaxin are known so far to have drug like properties. The first ATX-directed
fluorescent activity probe has been synthesized and characterized by Cavalli et
al.in 2010, that detects and quantifies ATX activity under normal and pathological
conditions.9 This probe contains a trapping moiety that becomes reactive after
phosphate ester hydrolysis,and then, specifically and covalently binds to the
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active site of ATX. Their study highlights the potential of such ATX-specific ABPs
to be used as diagnostic reagents.9
Biosynthesis of LPA
LPA is synthesized in living systems both intracellularly and extracellularly.
Inside the cell, LPA is produced and used as an intermediate for the synthesis of
phospholipids. There is no evidence that this intracellular LPA is then released
into the extracellular environment. LPA is present in saliva, seminal fluid,
incubated plasma, follicular fluids and serum, but not in plasma, as is produced
only during serum formation. Ovarian cancer cells and platelets produce LPA
upon stimulation.7
LPA is produced by two enzymatic mechanisms: a) hydrolysis of the fatty
acyl chain of phosphatidic acid (PA) at the sn-2 position by phospholipase A2
(PLA2), or at the sn-1 position by phospholipase A1 (PLA1) (mainly operative
intracellularly); and b) Hydrolysis of membrane LPC (Lysophosphatidylcholine)
by autotaxin, which removes the hydrophilic choline headgroup (in extracellular
body fluids like serum) (Figure 1).8 Lysophospholipase D (lysoPLD), which
catalyses the production of LPA from LPC, is identical to autotoxin(ATX).10 Both
LPA and LPC contain a single fatty acyl chain. When PLA1 cleaves the sn-1 fatty
acid, it produces sn-2 and polyunsaturated LPA isoforms, which are active on
LPA receptor 3.11 Type-II secretory phospholipase A2 (sPLA2) cleaves the sn-2
acyl chain, but is incapable of hydrolyzing lipids in intact cell membranes,
resulting in low LPA levels in the plasma. However, sPLA2 can selectively
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hydrolyze lipids in damaged micro vesicles and cells that are produced in
malignant fluids leading to abnormally high LPA levels in cancer cells.8
The protein ATX was first isolated in the early 1990s as an
„autocrine/tumor motility factor‟ produced by human melanoma cells and later
characterized

as

a

member

of

the

ecto-nucleotide

phosphodiesterase

/pyrophosphatase (NPPs) family of enzymes that hydrolyze phosphodiester and
pyrophosphate bonds in ATP and ADP.12 ATX has been found to be upregulated
in several cancers (including lung, renal-cell, mammary, hepato-cellular
carcinoma) and is expressed in the highest levels in brain, ovary, kidney, lung,
intestine, and testis.13 ATX is a type II transmembrane protein with a short aminoterminal

region,

a

single

transmembrane

domain,

two

cysteine

rich

somatomedin-B-like domains and a large catalytic domain. Studies have shown
that the motility-stimulating activity of ATX is attributed to production of LPA from
LPC, and the detection of elevated ATX expression in malignant tumor cells
provides enough evidence for the role of LPA in the onset of cancer.14 Therefore,
ATX converts extracellular LPC into receptor-active LPA, which stimulates
malignant cell proliferation and differentiation of adipose tissue. The mechanism
that has been proposed for cancer cell motility is through the activation of Gprotein-coupled receptor LPA1. ATX is also upregulated in genetically obese
mice. In addition, LPA exists in extracellular fluid of adipocytes and is released by
adipocytes in vitro. These studies suggest ATX mediating LPA paracrine control
of adipose tissue.15

5

LPA has been termed as a double-edged sword. Studies have elucidated
physiological roles of LPA in the reproductive system, embryonic development,
wound healing, tissue repair, blood clotting and to maintain homeostasis of the
body against stress. However, it simultaneously plays a key role in the initiation
and propagation of various human malignancies and pathological processes.
Studies suggest both a protective (under ischemia) and destructive (as causes
atherosclerosis) role of LPA in different aspects of cardiovascular disorders. LPA
has been identified as a growth factor for cancer (ovarian, prostate, breast, lung,
gastric, pancreatic, colorectal cancer) cells by inducing cell proliferation, growth,
survival, migration, invasion and angiogenesis. Also, recent studies indicate a
significant contribution of LPA signaling to neuropsychiatric disorders and
neuropathic pain. In addition, LPA‟s involvement in not only the male and female
reproductive systems, but also in embryonic development, can help develop new
assisted reproductive technologies and birth control. This functional switch of
LPA from physiological to pathophysiological mechanisms underscores its
signaling and identification of its receptors as a crucial therapeutic target for
prevention and treatment of various diseases like cancer. As illustrated by these
examples, LPA shows both a positive and a negative role in pathological
processes and has a contribution in normal physiological processes, and
therefore is the primary focus of my research.
LPA Receptors
So far, five distinct LPA receptors (LPA1-LPA5) have been identified that
mediate LPA activity. Due to their sequence homology, LPA 1, LPA 2 and LPA 3
6

receptors belong to the endothelial differentiation gene (EDG) sub-family of the
GPCR superfamily (therefore also called EDG 2, EDG 4 and EDG 7,
respectively) which traverses the membrane seven times.7 LPA 4 was identified
recently, which is more closely related to the Purinergic family, and shares no
significant similarity with the EDG family.7 LPA 1, the first discovered receptor, is
most widely expressed and best characterized, whereas LPA2 and LPA 3 have a
more restricted distribution, and expression of LPA 4 is very low in most human
tissues, but significant in the ovary.8 Although LPA5 is structurally different from
LPA1-3, but it shares 35% homology with LPA4.16 A probable sixth LPA receptor,
LPA6, has been reported recently. LPA6 is closely related to LPA4, and is
essential for human hair growth.17
LPA 1 is most widely expressed with high mRNA levels in the colon, small
intestine, placenta, brain, heart, and significantly high levels in cerebral cortical
ventricular zone during neurogenesis, adult oligodendrocytes and Schwann cells,
in addition to moderate expression in pancreas, ovary and prostate. 8 Expression
of LPA 2 and LPA 3 receptors is elevated in cancer cells, especially in ovarian
cancer cells, thereby suggesting a potential role in ovarian cancer progression.
LPA1, LPA2 and LPA3 receptors of the EDG family exhibit 50% sequence
homology in amino acid sequences in all areas except that of the carboxy (C)terminal tail region of these receptors is much less homologous with only 27%
between LPA1 and LPA2, and 17% between LPA2 and LPA3 receptors. This
difference in sequences of amino acids only in the C-terminal tail domain could
be a possible reason for the specificity of the receptors in mediating LPA
7

signaling.7 Experiments were conducted in a yeast two-hybrid screening by Xu et
al. to understand the mechanisms and specificity by which these LPA receptors
mediate LPA activity, and found that TRIP 6 (a focal adhesion molecule)
specifically binds to carboxyl-terminal tail of the LPA 2 receptor through its LIM
domains and not other LPA 1 or LPA 3 receptors.18 This specific interaction
between TRIP 6 and LPA2 alone might help to study the specific roles of LPA2 in
the pathophysiology of ovarian cancer cells.
G-protein-coupled receptors (GPCRs) and G-protein signaling
The reason why LPA signals are involved in diverse biological and
physiological processes, such as tissue remodeling, neurogenesis, immune,
reproductive functions, wound healing, cancer, atherosclerosis, is because LPA
receptors can couple to at least 3 different heterotrimeric proteins - Gq, Gi and
G12/13, which further feed into multiple effector pathways.7 The major downstream
effectors are shown in figure 2. LPA activates Gq, which stimulates
Phospholipase C (PLC), stimulating the hydrolysis of phosphatidylinositol-(4,5)bisphosphate (PIP2) to diacylglycerol (DAG) and Inositol-(1,4,5)-trisphosphate
(IP5).

8

Figure 2. Major LPA signaling pathways involving G-coupled receptors

LPA also activates Gi, which feeds into 3 different signaling routes a)
inhibition of adenyl cyclase b) G-mediated stimulation of mitogenic RAS-MAP
kinase (mitogen-activated protein kinase) cascade, thus triggering downstream
events, and c) activation of phosphatidylinositol-3-kinase (PI3K), which leads to
the activation of the guanosine diphosphate/guanosine triphosphate (GDP/GTP)
exchange factor TIAM 1 and the downstream RAC GTPase, in addition to
9

activation of AKT‟s ‟survival‟ pathway to promote cell movement and prevent cell
death or apoptosis. Lastly, LPA activates G12/13, which stimulates GTPase RHO
A, plays a role in cytoskeletal contraction and cell rounding.7 Therefore, LPA, in
addition to activating second messengers such as cAMP, calcium and
diacylglycerol, also stimulates RAS and RHO family GTPases, which are master
switches that control cell proliferation, migration and morphogenesis8 (Figure 2).
LPA induced activation of Gi in turn stimulates the RAS-mediated
downstream MAP kinase cascade and plays a role in DNA synthesis, cell
proliferation and cell survival. The mechanism of Gi coupling to Ras is complex
and not yet clear. In order to maintain proper cell functionality, the accumulated
LPA must be counterbalanced by inactivation processes. It has long been known
that extracellular LPA in mammalian cells is degraded by removal of a phosphate
group to produce biologically inactive monoacylglycerol.
Activity Based Protein Profiling (ABPP)
Advances in genome sequencing techniques have provided useful
insights into the crucial aspects of the proteome encoded by genomes.
Techniques such as chromosomal translocation, transcriptional profiling, and
RNA interference based gene silencing have enlightened us about the
physiological and pathological processes of genome sequences, which are
controlled by proteins and RNA molecules.19 Nevertheless, they do not furnish
information about the post-translational events that regulate protein function and
activity. To overcome this problem, several proteomic strategies have been
developed including LC-MS, gel electrophoresis, multidimensional protein
10

identification technology (MudPIT) and isotope coded affinity tags (ICAT), yeast
two–hybrid systems, and protein microarrays that enrich the knowledge of the
functions of proteins in vitro.20 However, they fail to assess protein‟s functional
state and activity inside cells and tissues.21 Therefore, as a complement to
conventional genomic techniques, ABPP has been developed as a functional
proteomic technology to identify and understand the functional state of novel
proteins, and characterize proteins on the basis of activity rather than
abundance.20
The chemical proteomic approach of ABPP uses active-site directed
probes to collectively analyze proteins based on activities. ABPP probes use a
range of mechanism-based inhibitors, protein-reactive natural products and
general electrophiles to target and react with specific classes of enzymes sharing
a similar catalytic activity.
The basic unit of ABPP is a probe that typically consists of two elements:
(1) a reactive group by which the probe selectively and covalently cross-links to
residues in the active site of an active enzyme. (2) a secondary tag that may be
either a reporter group such as fluorophore, biotin, or a latent analytical handle
such as alkyne or azide that can undergo derivatization via click chemistry to
visualize and purify target proteins. These groups are incorporated into an active
molecule such that it mimics the natural compound. Therefore, ABPP involves
the synthesis of small-sized probes that can covalently label active site residues
of target proteins, as shown in figure 3. Subsequently, the labeled proteins are
visualized and purified using the secondary reporter tag, commonly alkyne or
11

azide tags attached on the probe are reacted with complementary “clickable”
fluorophores or biotin bearing azide or alkyne, respectively, forming a 1,4disubstituted triazole product which covalently introduces these tags on to the
probe-labeled protein facilitating analysis. This is performed by gel fluorescence
scanning for fluorescent probes or by purification on a streptavidin column for
biotinylated probes, which is followed by mass spectrometry analysis for
identification of the probe-labeled enzymes.19
Today, ABPP is being used in multiple biological experiments including
the discovery of protein targets using comparative ABPP, as well as inhibitor
identification and enzyme active site characterization. ABPP has many
advantages over other conventional methods for target discovery as it can
account for the post-translational mechanisms that regulate enzyme activity and
labels even low-abundance proteins. The inhibitor discovery involves competitive
ABPP to identify inhibitors which are able to block probe labeling of enzymes.
The advantage of this method is that it does not require recombinant expression
and purification as the enzymes are tested within the proteome. Also, ABPP is a
powerful tool to assign an uncharacterized enzymes to a specific mechanistic
class and recognize new enzyme active sites.19

12

Figure 3. Schematic representation of Activity Based Protein Profiling
(ABPP) using probes bearing photoaffinity tags
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Figure 4. Examples of photo-reactive groups

Photo affinity labeling (PAL) involves a specific covalent binding between
a light-sensitive chemical tag and the active site of a receptor protein molecule
upon irradiation, in a specifically and reversibly bound state.22 This enables
specific cross-linking of the ligand to the specific protein targets to which it
preferentially binds. This identification of drug-receptor pairs helps to design drug
molecules that show selective recognition of specific targets associated with a
specific pathology. A photo reactive group should be stable to ambient light, and
its excited state should have a lifetime long enough to abstract a hydrogen on
carbon atom to form a cross link with the target protein. Also, its UV excitation
wavelength should be higher than the absorption range of most proteins.
Commonly used groups are shown in Figure 4. Phenyl azides are usually the first
choice to use as they are easy to prepare. Diazirines are very stable before UV
irradiation and need wavelengths higher than that for proteins, but require multstep synthesis to form the strained 3-membered heterocyclic rings. The
benzophenone probe requires prolonged irradiation resulting in cell death, but
the excited carbonyl diradical is less reactive towards water than a nitrene or

14

carbene.22a Therefore, benzophenone is being used as a photoprobe for the
synthesis of my analogues since it is easily activated with long wavelength UV
light, and is stable during the chemical reactions used for the probe synthesis. It
also has been found to covalently modify a single protein target. 23
Photoactivable lipid analogues have been used earlier to determine
structure of membrane-bound proteins.24 Studies published by Li et al., report the
synthesis of a benzophenone photoactivable analogue of acyl-LPA, with an
oleoyl (ester) chain.22 Previous structure- activity studies have found that the
oleoyl chain most closely represents the fatty acyl chain of naturally occurring
LPAs.25 This probe was found to covalently modify protein targets in rat
plasma.22

15

Chapter II: Research Design
The biological properties of LPA and LPC have been studied widely but
their roles and activity in many pathophysiological conditions are not yet
completely understood. Therefore, we are designing photoreactive analogs of
LPA and LPC in order to track and elucidate their activities in the biological
systems. This research project targets the development of bifunctional LPA and
LPC analog probes, as shown in figure 5. These probe designs consist of LPA
and LPC analogs. A Y-shaped lysine linker bearing both a photoaffinity
benzophenone group as well as a clickable reactive azide or alkyne reporter tag,
is used as a secondary handle to append a fluorophore or biotin tag. These
probes will allow for selective labeling of target proteins, followed by visualization
and purification on a streptavidin column for the selective enrichment and
identification of crosslinked proteins.

Figure 5. Target LPA & LPC activity probes
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As shown in figure 6, the head group synthesis started with the protection
of the free alcohol of (S)-glycerolacetonide 2 with a p-methoxybenzyl protecting
group to 3, followed by acetal deprotection to produce diol 4. Next, the primary
alcohol of 4 was selectively protected by monomethoxytrityl chloride (MMTrCl) to
5, followed by secondary alcohol protection using tert-butyldiphenylsilyl chloride
to yield 6. Next, the MMTr group was deprotected using camphorsulfonic acid
producing 7 with a free alcohol at the sn-1 position.
The synthesis of the lipid tail containing the benzophenone cross-linking
group and azide tag (Figure 7) began with the coupling of 4-benzoylbenzoic acid
to a Y-shaped protected lysine linker 8 to produce 9. The Boc protecting group
was removed using trifluoroacetic acid to produce the free amine of 10, and in
order to keep the synthetic strategy modular (figure 8), 10 was converted into
both an azide 12a and alkyne 12b, the latter by reacting with alkyne acid 11.
After the azide/alkyne methyl esters 12a and 12b were purified, they were
hydrolyzed to yield acids 13a and 13b, respectively.
Coupling of Head group and Lipid tail
Once synthesized, we attempted to couple head group 7 and lipid tail
13a/b to produce 21, as shown in Figure 9. The coupling of alcohol 7 with the
azide and alkyne acids 13a and 13b was attempted several times using different
coupling reagents, including N,N–dicyclohexylcarbodiimide (DCC), 1-Ethyl-3-(3dimethylaminopropyl)carbodiimide (EDCI) and thionyl chloride ( SOCl2), but the
reaction never gave very good yields, and the product was difficult to
characterize. It may be attributed to the steric hindrance at the alcohol reaction
17

center, caused by the two bulky protecting groups. Therefore, to get around this
problem, another synthetic strategy was followed in which we attempted to
couple the acid directly with the diol, and the mixture of 1 and 2 substituted
products would be separated to obtain the latter, and this would be followed by
the protection of the secondary alcohol. Therefore, a set of trial reactions were
run in order to find out the best reaction conditions for the coupling of the diol
with lauric acid as it is similar to the lipid tail, as shown in figure 10. The best
results were obtained with EDCI and DCC coupling reagents as they yielded the
highest yields of the desirable regioisomeric ester, and the two regioisomers
were conveniently separated. Next, the diol and the lysine acid were coupled
under these reaction conditions, as shown in figure 11, but again the yields were
not very good.
Once they have been coupled, the p-methoxybenzyl group of 21a,b
would then be deprotected with DDQ to yield the free alcohol 14a,b (Figure 12).
This would be followed by the installation of protected phosphoramidites 19 or
20, as shown in figure 10 and 11. Finally the dibenzyl and ethylcyano groups of
17a/b and 15 a/b respectively, will be deprotected producing the free phosphate,
followed by the deprotection of TBDPS group to produce the target LPA activity
probes 18a/b and LPC activity probes 16a/b, that can be utilized to identify and
characterize new protein targets.
Once the bifunctional probes have been synthesized, they will first be
tested for their effective activity as LPA and LPC mimics by the means of TLC
(exploiting the differential adsorption of LPA and LPC on a TLC plate), MS
18

studies and fluorescence resonance energy transfer (FRET) through our ongoing
collaborations with Dr. Daniel L. Baker and Dr. Abby L. Parrill at the University of
Memphis. After it is validated as an effective mimic, it will be then be subjected to
ABPP and other analytical studies, again in collaboration, where the incubation of
the proteome with our synthesized probes will be followed by UV irradiation and
fluorophore or biotin–labeling of the probe–bound proteins. Next, this mixture of
proteins will be separated using electrophoresis (1D or 2D polyacrylamide gel
electrophoresis PAGE), and the labeled proteins will be detected by fluorescence
scanning of the gels.19 Proteins labeled with biotinylated probes will be separated
by affinity chromatography using a streptavidin column. Though ”gel-free”
methods have emerged, gel-based methods are still widely used because of their
robustness and efficiency. Liquid chromatography-mass spectrometry (LC–MS)
methods provide better resolution than the gel–based methods, and is classified
into two types. The first type involves the analysis of protein targets of probes,
and the second one specifically analyses probe-labeled peptides derived from
these targets. The first method is a combination of ABPP and MudPIT
(multidimensional protein identification technology), in which biotinylated probelabeled enzymes are enriched on streptavidin column, followed by enzymatic
digestion (with trypsin)

of

the protein into peptide fragments that are then

analyzed by LC-MS using triple-quadruple and ion trap mass spectrometers. The
disadvantage of this method is that it does not offer a straightforward way to
identify probe labeled peptides of enzyme targets.19 Therefore, active–site
peptide profiling (ASPP) is used, which reverses the order of enzymatic digestion
19

and incubation, followed by the use of SEQUEST algorithm to identify protein
receptors and sites of probe labeling. Speers and Cravatt developed tandem
orthogonal proteolysis–ABPP (TOP–ABPP), which combined the advantages of
ABPP–MudPIT and ASPP to complement each other. In TOP, the probe-labeled
proteins are clicked with a biotin tag bearing a tobacco etch virus protease (TEV)
cleavage site, and then enriched. Following the on-bead tryptic digestion of the
tagged proteins, the probe-labeled peptides are eluted from the beads by
incubation with TEV. Then sequential MudPIT experiments are conducted to
analyze the trypsin and TEV digests, for characterizing the probe-labeled
proteins and sites of probe labeling.26 Though LC-MS offers high resolution, but
requires larger sample volume each time and is slower, and thus not a desirable
method to analyze hundreds of samples.19
These analytical methods will help us to identify the inhibitors of LPA production
and action.

20

Figure 6. Synthesis of the head group

21

Figure 7. Synthesis of the lipid tail
22

Figure 8. Modular synthesis of the alkyne acid
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Figure 9. Synthetic strategy for introducing the bifunctional tag
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Figure 10. Alternative methods attempted for direct coupling of lipid tails
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Figure 11. Attempt to couple bifunctional tags directly onto diol 4
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Figure 12. Modular synthetic strategy of the LPA probe
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Figure 13. Modular synthetic strategy of the LPC probe
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Experimental Procedure

(S)-4-(((4-methoxybenzyl)oxy)methyl)-2,2-dimethyl-1,3-dioxolane (3)
Sodium hydride (518 mg, 12.1 mmol) was dissolved in 40 mL of N,Ndimethylformamide at 0 oC under Nitrogen gas. S-Glycerol acetonide 2 (1 mL,8.1
mmol) was then dissolved in 40 mL of N,N-dimethylformamide and slowly added
to the Sodium hydride solution over 10 min. This mixture was then stirred at 0 oC
for 1 hour, after which 4-methoxybenzyl chloride (1.64 mL, 12.1 mmol) was
added at room temperature and stirred overnight at room temperature. This was
quenched by water (50 mL) the next day. This was followed by extraction with
dichloromethane and saturated sodium chloride (2×50 mL), the organic layer was
collected and dried using magnesium sulphate, then filtered and the solvent was
removed. Column chromatography on silica gel and a gradient solvent system of
10-50% ethyl acetate/hexanes gave the product as a clear oil (1.23 g, 61%).
1

H NMR (300 MHz, CDCl3) δ 7.33 – 7.21 (m, 4H), 6.95 – 6.83 (m, 2H), 4.59 –

4.43 (m, 2H), 4.27 (dd, J = 12.1, 5.9 Hz, 1H), 4.05 (dd, J = 8.2, 6.4 Hz, 1H), 3.81
(s, 3H), 3.73 (dd, J = 8.2, 6.4 Hz, 1H), 3.48 (ddd, J = 27.0, 9.8, 5.6 Hz, 2H), 1.61
– 1.51 (m, 4H), 1.39 (d, J = 17.8 Hz, 5H), 0.23 – -0.25 (m, 38H).
NMR data matched that in the literature.27
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(R)-3-((4-methoxybenzyl)oxy)propane-1,2-diol (4)
Acetal 3 (1.63 g, 6.5 mmol) was dissolved in methanol/dichloromethane (1:1, 40
mL) and p-toluenesulphonic acid (570 mg, 3 mmol) was added, then it was
allowed to stir at room temperature for 24 hours. The reaction mixture was then
quenched with sodium bicarbonate (505 mg, 6 mmol) followed by extraction with
water and dichloromethane (2x50mL) , the organic layer was collected and dried
using

MgSO4,

then

filtered,

and

the

solvent

was

removed.

Column

chromatography on silica gel and a gradient solvent system of 50% ethyl
acetate/hexanes to 5% methanol/dichloromethane gave the diol 4

(682 mg,

50%).
1

H NMR (300 MHz, CDCl3) δ 7.31–7.21 (m, 1H), 6.90 (dd, J = 9.0, 2.3 Hz, 1H),

4.50 (s, 1H), 3.96–3.84 (m, 1H), 3.82 (d, J = 0.5 Hz, 1H), 3.77–3.72 (m, 1H),
3.72–3.67 (m, 1H), 3.63 (dd, J = 11.0, 5.0 Hz, 1H), 3.55 (dd, J = 5.8, 5.1 Hz, 1H),
3.51 (d, J = 6.1 Hz, 1H).

(S)-1-((4-methoxybenzyl)oxy)-3-((4methoxyphenyl)diphenylmethoxy)propan-2-ol (5)
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The p-methoxybenzyl protected diol 4 (305 mg, 1.4 mmol) was dissolved in
pyridine (20 mL) under Nitrogen, followed by the addition of monomethoxytrityl
chloride (889.4 mg, 2.88 mmol), 4-dimethylaminopyridine (17.59 mg, 0.14 mmol)
and some molecular sieves. The reaction mixture was then stirred overnight at
room temperature. Next day, it was quenched by methanol (1 mL) and then 1
drop of water added and stirred, followed by the removal of solvent. Column
chromatography on silica gel and a gradient solvent system of 20-35% ethyl
acetate/hexanes gave the product 5 (524.4 mg, 75%).
1

H NMR (300 MHz, CDCl3) δ 7.39 (dt, J = 9.1, 8.0 Hz, 4H), 7.34 – 7.12 (m, 11H),

6.93 – 6.73 (m, 4H), 4.60 (s, 1H), 4.46 (s, 2H), 3.98 (dt, J = 10.3, 4.2 Hz, 1H),
3.82 – 3.73 (m, 6H), 3.62 – 3.45 (m, 2H), 3.20 (pd, J = 9.4, 5.8 Hz, 2H), 2.47 (d, J
= 4.8 Hz, 1H), 1.64 (s, 1H).
NMR data matched that in literature.

(S)-tert-butyl((1-((4-methoxybenzyl)oxy)-3-((4methoxyphenyl)diphenylmethoxy)propan-2-yl)oxy)diphenylsilane (6)
Alcohol 5 (204 mg, 0.42 mg) was dissolved in pyridine (5 mL) under nitrogen,
followed

by

the

addition

of

imidazole

(57.3

mg,

0.84

mmol),

t-

butyldiphenylchlorosilane (0.218 mL, 0.84 mmol) and molecular sieves. This
reaction mixture was then stirred at room temperature overnight. Once the
reaction was complete, the molecular sieves were removed by filtering the
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mixture over celite. The mixture was then quenched with 10 mL of methanol and
then a few drops of water added. This was followed by removal of solvent by
rotary evaporation, and column chromatography on silica gel and a gradient
solvent system of 3-10% ethyl acetate/hexanes gave product 6 (302 mg, 99%).
1

H NMR (300 MHz, CDCl3) δ 7.95 (d, J = 8.2 Hz, 2H), 7.90–7.76 (m, 4H), 7.63 (t,

J = 7.4 Hz, 1H), 7.51 (t, J = 7.5 Hz, 2H), 6.88 (s, 1H), 4.83 (d, J = 5.4 Hz, 1H),
4.60 (s, 1H), 3.81 (s, 3H), 3.14 (d, J = 6.4 Hz, 2H), 2.04–1.93 (m, 1H), 1.84 (s,
1H), 1.58 (dd, J = 3.7, 3.0 Hz, 1H), 1.56–1.47 (m, 2H), 1.41 (s, 11H).
NMR data matched that in literature.27

(R)-2-((tert-butyldiphenylsilyl)oxy)-3-((4-methoxybenzyl)oxy)propan-1-ol (7)
Compound 6 (296 mg, 0.41 mmol) was dissolved in methanol:dichloromethane
(15 mL, 2:1), followed by the addition of camphorsulfonic acid (47.55 mg, 0.20
mmol). The reaction mixture was then stirred at room temperature for 3.5 hours,
followed by its neutralization by triethylamine and concentration. Column
chromatography on silica gel and a gradient solvent system of 20–35% ethyl
acetate/hexanes gave the product 7 (99 mg, 51%).
1

H NMR (300 MHz, CDCl3) δ 7.72–7.59 (m, 4H), 7.50–7.29 (m, 6H), 7.18–7.05

(m, 2H), 6.89–6.75 (m, 2H), 4.37–4.19 (m, 2H), 3.99–3.84 (m, 1H), 3.79 (s, 3H),
3.64 (d, J = 4.3 Hz, 2H), 3.57–3.34 (m, 2H), 1.07 (d, J = 2.9 Hz, 9H).
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(S)-methyl-2-(4-benzoylbenzamido)-6-((tertbutoxycarbonyl)amino)hexanoate (9)
Cbz protected lysine 8 (600 mg, 1.52 mmols) was dissolved in methanol (15 mL),
followed by the addition of 10% palladium hydroxide (60 mg) by weight. The
mixture was then stirred for 24 hours at room temperature under hydrogen,
followed by filtration over celite. Then the filtrate was concentrated, and the
residue (386.1 mg, 97%) was dissolved in N,N-dimethylformamide (10 mL) under
nitrogen, followed by the addition of 4-benzoylbenzoic acid (186 mg, 0.82 mmol),
EDCI (189 mg, 0.99 mmol) and 4-dimethylaminopyridine (120 mg, 0.99 mmol).
The reaction mixture was stirred at room temperature for 5 hours, and then
concentrated. Column chromatography on silica gel and a gradient solvent
system of 50% ethyl acetate/hexanes gave the product 9 (240 mg, 60%).
1

H NMR (300 MHz, CDCl3) δ 7.95 (d, J = 8.2 Hz, 2H), 7.90–7.76 (m, 4H), 7.63 (t,

J = 7.4 Hz, 1H), 7.51 (t, J = 7.5 Hz, 2H), 6.88 (s, 1H), 4.83 (d, J = 5.4 Hz, 1H),
4.60 (s, 1H), 3.81 (s, 3H), 3.14 (d, J = 6.4 Hz, 2H), 2.04–1.93 (m, 1H), 1.84 (s,
1H), 1.58 (dd, J = 3.7, 3.0 Hz, 1H), 1.56–1.47 (m, 2H), 1.41 (s, 11H).
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(S)-methyl 6-azido-2-(4-benzoylbenzamido)hexanoate (12a)
Boc-protected amine 9 (30.4 mg, 0.06 mmols) was dissolved in dichloromethane
(4 mL), followed by the addition of trifluoroacetic acid (4 mL), and the reaction
mixture was stirred at room temperature for 2 hours. Then it was concentrated,
and the residue put under high vacuum overnight. The next day, the residue was
dissolved in methanol (10 mL), followed by the addition of imidazole-1-sulfonyl
azide hydrochloride (16.35 mg, 0.08 mmols), 0.804 M potassium carbonate
solution (0.14 mL, 0.11 mmol) and 0.01 M copper (II) sulfate pentahydrate
solution (0.65 mg, 0.006 mmols). The reaction mixture was stirred at room
temperature for 3 hours, followed by extraction with ethyl acetate and 2M HCl.
The organic phase was collected and dried with MgSO 4 followed by
concentration. Column chromatography on silica gel and a gradient solvent
system of 50% ethyl acetate/hexanes gave the product 12a (21 mg, 80%).
1

H NMR (300 MHz, CDCl3) δ 7.91 (dd, J = 14.1, 6.6 Hz, 3H), 7.88–7.75 (m, 4H),

7.68–7.57 (m, 1H), 7.57–7.43 (m, 2H), 6.88 (d, J = 7.7 Hz, 1H), 4.87 (dd, J =
12.9, 7.4 Hz, 1H), 3.82 (s, 3H), 3.37–3.19 (m, 2H), 2.1 –1.95 (m, 1H), 1.86 (ddd,
J = 20.8, 11.7, 6.4 Hz, 1H), 1.74–1.58 (m, 2H), 1.58–1.38 (m, 2H).
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NMR data matched that in literature.28

(S)-6-azido-2-(4-benzoylbenzamido)hexanoic acid (13a)
Azide 12b (355 mg, 0.9 mmol) was dissolved in methanol (4 mL), followed by the
addition of 2M NaOH (4 mL) was added, and then the reaction mixture stirred at
room temperature for 30 minutes. Then the reaction was extracted with 2M HCl,
and the organic layer collected and dried with magnesium sulfate and
concentrated to give the product 13a (308 mg, 90%).
1

H NMR (300 MHz, CDCl3) δ 7.89 (dd, J = 19.8, 8.5 Hz, 3H), 7.79 (dd, J = 5.3,

3.2 Hz, 1H), 7.68–7.57 (m, 1H), 7.50 (t, J = 7.5 Hz, 1H), 6.86 (d, J = 7.4 Hz, 1H),
4.88 (dd, J = 12.9, 7.1 Hz, 1H), 3.32 (t, J = 6.5 Hz, 1H), 2.07 (s, 1H), 1.92 (d, J =
7.4 Hz, 1H), 1.67 (dt, J = 12.2, 6.0 Hz, 2H), 1.55 (d, J = 4.1 Hz, 2H), 1.25 (s, 4H),
0.87 (d, J = 7.0 Hz, 1H).
NMR data matched that in literature.28
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Acid 13a (57 mg, 0.15 mmol) was dissolved in dichloromethane (5 mL) under
nitrogen,

followed

by

the

addition

of

a

few

molecular

sieves,

4-

dimethylaminopyridine (25.5 mg, 0.20 mmol) and N,N-dicyclohexylcarbodiimide
(43 mg,0.20 mmols). This reaction mixture was stirred at room temperature for
30 minutes. Next, the alcohol 7 (70 mg, 0.15 mmols) was added and the reaction
mixture was stirred for 24 hours. Then it was filtered over celite and
concentrated. Column chromatography on silica gel and a gradient solvent
system of 20-35% ethyl acetate/hexanes gave the product 21 (17 mg, 14%).
1

H NMR (300 MHz, CDCl3) δ 7.99 – 7.89 (m, 1H), 7.90 – 7.76 (m, 4H), 7.75 (s,

1H), 7.67 (d, J = 8.2 Hz, 5H), 7.53 (t, J = 7.6 Hz, 3H), 7.39 (d, J = 7.4 Hz, 9H),
7.11 (t, J = 11.3 Hz, 2H), 6.85 (d, J = 8.4 Hz, 2H), 4.70 (s, 1H), 4.48 – 4.40 (m,
1H), 4.39 – 4.22 (m, 3H), 4.08 (s, 1H), 3.80 (d, J = 9.8 Hz, 20H), 3.66 – 3.57 (m,
1H), 3.57 – 3.43 (m, 2H), 3.39 (s, 4H), 3.26 (s, 2H), 3.18 – 3.04 (m, 1H), 2.21 (s,
1H), 2.07 (s, 1H), 1.97 – 1.82 (m, 1H), 1.75 (s, 1H), 1.61 (s, 3H), 1.44 (s, 2H),
1.27 (s, 5H), 1.12 – 0.96 (m, 9H), 0.88 (d, J = 7.6 Hz, 2H), 0.18 – -0.19 (m, 64H).
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Acid 13b (30 mg, 0.06 mmol) was dissolved in dichloromethane (5 mL) under
nitrogen,

followed

by

the

addition

of

a

few

molecular

sieves,

4-

dimethylaminopyridine (10.4 mg, 0.08 mmol) and N,N-dicyclohexylcarbodiimide
(23 mg, 0.12 mmols). This reaction mixture was stirred at room temperature for
30 minutes. Next, the alcohol 7 (14 mg, 0.07 mmols) was added and the reaction
mixture was stirred for 24 hours. Then it was filtered over celite and
concentrated. Column chromatography on silica gel and a gradient solvent
system of 75% ethyl acetate/hexanes-10%methanol/dichloromethane gave the
product 21 (5 mg, 12%).
1

H NMR (300 MHz, CDCl3) δ 8.00 (d, J = 7.9 Hz, 2H), 7.93 – 7.72 (m, 4H), 7.63

(t, J = 7.4 Hz, 1H), 7.50 (t, J = 7.6 Hz, 2H), 7.35 – 7.17 (m, 5H), 6.97 – 6.81 (m,
2H), 6.30 (s, 1H), 6.26 – 6.13 (m, 1H), 4.75 (s, 1H), 4.49 (s, 2H), 4.43 – 4.16 (m,
1H), 4.11 (s, 1H), 3.97 (dt, J = 5.3, 2.6 Hz, 2H), 3.84 – 3.74 (m, 3H), 3.67 (s, 1H),
3.54 (dd, J = 8.0, 5.0 Hz, 2H), 3.26 (s, 2H), 2.44 (d, J = 4.8 Hz, 4H), 2.19 (t, J =
2.5 Hz, 1H), 2.00 (d, J = 26.1 Hz, 3H), 1.65 (s, 6H), 1.57 – 1.32 (m, 6H), 1.32 –
1.11 (m, 6H), 0.87 (d, J = 7.0 Hz, 2H).
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4-oxo-4-(prop-2-yn-1-ylamino)butanoic acid (11)
Propargylamine (1.5 ml, 21.87 mmols) was dissolved in 10 ml of N,Ndimethylformamide/acetonitrile (1:1) at 0oC under Nitrogen. Next, succinic
anhydride dissolved in 10 ml of acetonitrile was added to this solution, and stirred
overnight at room temperature. This was followed by removal of the solvent, and
the residue was then washed with 40 ml of hexane to obtain a yellow brown
solid. Column chromatography on silica gel and a gradient solvent system of 2050% ethyl acetate/hexanes/0.1% acetic acid-10% methanol/dichloromethane/
0.1% acetic acid gave the product 11 (2502 mg, 38%).
1

H NMR (300 MHz, CDCl3) δ 3.93 (t, J = 2.3 Hz, 2H), 3.30 (dt, J = 3.3, 1.6 Hz,

8H), 2.64 – 2.52 (m, 3H), 2.52 – 2.41 (m, 2H).
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